Core Viewpoint - Shattuck Labs, Inc. (NASDAQ:STTK) is recognized for its strong performance and potential upside, making it a notable investment opportunity among penny stocks [1]. Financial Performance - For Q3 2025, Shattuck Labs reported a net loss of $10.1 million, equating to $0.14 per basic and diluted share [3]. - Research and Development (R&D) expenses decreased to $7.60 million, while General and Administrative (G&A) expenses totaled $4.10 million [3]. - The company maintains a solid financial position with cash and investments amounting to $86.10 million [2]. Drug Development Progress - The Phase 1 readout for the SL-325 drug is anticipated in Q2 2026, which is viewed as a significant growth catalyst [2]. - The company is advancing the SL-325 trial and is making progress towards selecting a bispecific candidate for development in 2026 [3]. - The SL-325 drug targets the DR3/TL1A pathway, aiming for a complete blockade, indicating its potential in treating autoimmune and inflammatory diseases [4]. Analyst Sentiment - Analyst Joseph Pantginis from H.C. Wainwright has reiterated a "Hold" rating on Shattuck Labs, citing the drug's clinical potential and the company's balanced risk profile [2].

Core Insights - The article discusses the current investment landscape for penny stocks, emphasizing that their performance is influenced more by market psychology than macroeconomic conditions [1] - Small-cap stocks are gaining momentum, particularly after strong third-quarter earnings, making them more attractive compared to large-cap stocks [2] - Several catalysts are driving interest in small-cap stocks, including M&A activity, biotech developments, and opportunities in sectors linked to AI [3] Small-Cap Stock Performance - The Russell 2000 index has increased by 21.60% over the past six months, although it has experienced four consecutive weeks of decline recently [4] Methodology for Stock Selection - The list of 12 hot penny stocks was compiled based on stocks priced under $5, with over 50% returns in the last three months and an upside potential exceeding 20% as of November 24, 2025 [6] - Hedge fund sentiment was also considered, utilizing data from Insider Monkey's hedge fund database tracking 983 hedge funds as of Q2 2025 [7] Individual Stock Highlights - **Shattuck Labs, Inc. (NASDAQ:STTK)**: - 3-month performance of 102.21% with an average upside potential of 45.63% [9] - The company has a cash balance of $86.10 million and reported a net loss of $10.1 million for Q3 2025 [10][11] - **Erasca, Inc. (NASDAQ:ERAS)**: - 3-month performance of 93.08% with an average upside potential of 73.01% [13] - The company reported a net loss of $30.6 million for Q3 2025 but has a solid cash position of $362.4 million [15][17] - **CytomX Therapeutics, Inc. (NASDAQ:CTMX)**: - 3-month performance of 107.50% with an average upside potential of 78.09% [18] - The company reported a revenue decline to $6 million for Q3 2025 but maintains a cash balance of $143.6 million [20][21]

Core Insights - Shattuck Labs, Inc. is participating in a panel discussion at the United European Gastroenterology Week (UEGW) Conference 2025, focusing on key takeaways from the event [1] - The panel will be moderated by analysts Martin Fan, Ph.D. and David Nierengarten, Ph.D., featuring KOL Marla Dubinsky, M.D. [1] Conference Details - The panel discussion titled "Wedbush UEGW Conference 2025 Rewind" will take place on October 8, 2025, from 10:00 am to 12:00 pm EST [2] - Shattuck's CEO, Taylor Schreiber, M.D., Ph.D., will represent the company during the session [2] Product Information - SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody aimed at achieving a complete and durable blockade of the DR3/TL1A pathway [2] - Preclinical studies of SL-325 show high affinity binding and superior activity compared to TL1A antibodies, indicating potential for higher efficacy and lower immunogenicity [2] - SL-325 is currently undergoing a Phase 1 clinical trial [2] Company Overview - Shattuck Labs, Inc. specializes in developing treatments for inflammatory and immune-mediated diseases, with a focus on inflammatory bowel disease (IBD) [3] - The company leverages its expertise in protein engineering to develop novel TNF receptor therapeutics, with SL-325 being its lead program [3] - Shattuck Labs operates offices in Austin, Texas, and Durham, North Carolina [3]